논문) As presented at the 2025 AACR Annual Meeting: in an ongoing first-in-human phase 1 trial of a next 2 generation KRAS G12C inhibitor in patients with solid tumors, encouraging safety and response results 3 were observed, including in patients with non-small cell lung cancer.
기사최종편집일: 2025-06-20 16:58:34
첨부파일 : 
논문) As presented at the 2025 AACR Annual Meeting: in an ongoing first-in-human phase 1 trial of a next 2 generation KRAS G12C inhibitor in patients with solid tumors, encouraging safety and response results 3 were observed, including in patients with non-small cell lung cancer.
메모
